Merck, known as MSD outside of the United States and Canada, announced the initiation of the company’s Phase 3 clinical program, CORALreef, for MK-0616,...
Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced a new collaboration with Merck, known as MSD outside of...
Merck, known as MSD outside of the United States and Canada, announced the completion of the Prometheus Biosciences, Inc. acquisition. Prometheus is now a...
Merck, known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. announced that the companies have entered into a definitive agreement...
Merck, known as MSD outside of the United States and Canada, announced results from the Phase 3 KEYNOTE-966 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy,...
